Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
$2,000 tariff rebate checks? 50-year mortgages? Making sense of Trump's new 'affordability' proposals. - 2The Best Design Bloggers for Style Motivation
- 3New funding transforms lives by expanding electricity access across Africa
- 4Have gravitational waves provided the first hint of primordial black holes born during the Big Bang?
- 5South Carolina measles outbreak grows by nearly 100, spreads to North Carolina and Ohio
- Arctic is again the hottest it's been in 125 years, with record-low sea ice, NOAA report says
- Oprah Winfrey's Favorite Wellness Destination Is A Luxurious Italian Retreat
- Best Exciting ride: Which One Rushes You the Most?
- Which Espresso Do You Like Best? Vote
- Mom finds out she has cancer after noticing something was off while breastfeeding
- See as Your #1: These Low-Sugar Food sources You Ought to Attempt
- 5 Destinations Where Airfare Is Dropping The Most For Spring 2026, Per Dollar Flight Club Analysis
- Mom warns of Christmas gift hazard as daughter recovers in hospital
- US bishops officially ban gender-affirming care at Catholic hospitals
